Clinical Trial Update: Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial assessing whether blood and tissue biomarkers can predict response to second-line therapy with erlotinib hydrochloride or chemotherapy in patients…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Chemotherapy (chemotherapy)
• Erlotinib hydrochloride (Erlotinib)

Snippet

Sponsor: Istituto Scientifico H. San Raffaele | Conditions: Lung Cancer | Phase 3 | Status: UNKNOWN